This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Diphtheria, tetanus, pertussis (3 component) and poliomyelitis (dtap/ipv)


Vaccine containing diphtheria and tetanus with pertussis and poliomyelitis.

Drugs List

  • BOOSTRIX -IPV vaccine
  • diphtheria & tetanus with pertussis (3 component) and poliomyelitis (dTaP/IPV) vaccine
  • Therapeutic Indications


    Diphtheria - prophylaxis
    Pertussis - prophylaxis
    Poliomyelitis - prophylaxis
    Tetanus - prophylaxis

    Active immunisation against diphtheria, tetanus, pertussis and poliomyelitis from 3 years of age as a booster following primary vaccination.

    The Department of Health has stated that this vaccine is not intended for primary vaccination as the low dose of the diphtheria component means it is unsuitable for this purpose. It should not be given to children of 10 years of age or older as pertussis vaccine is not currently recommended for this age group.

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.



    0.5ml as a single dose.


    Children aged 3 to 18 years
    0.5ml as a single dose.

    The current Department of Health recommendation is that children who completed a primary course of immunisation in infancy receive a single booster dose of this vaccine at least 3 years after completion of the primary course although, the interval can be reduced to 1 year if the primary vaccine was delayed. It is also recommended that immunisation against pertussis is not routinely recommended in individuals over 10 years of age.

    Additional Dosage Information

    Diphtheria, tetanus, pertussis and poliomyelitis vaccine should not be administered to individuals with an incomplete or no history of primary diphtheria, tetanus, or poliomyelitis vaccination. The vaccine may be given to individuals who have not previously received pertussis vaccination, however a booster response will only occur in individuals who have been primed through vaccination or natural infection.

    There is currently no data regarding the optimal interval between subsequent booster doses of the vaccine. The interval between a booster dose and preceding booster doses of diphtheria and tetanus containing vaccines should be preferably at least 5 years.

    This vaccine can be used in the management of tetanus prone injuries with or without concomitant administration of Tetanus immunoglobulin according to official recommendations.


    For intramuscular injection, preferably into the deltoid region. The vaccine should not be administered into the gluteal area.

    As bleeding may occur following intramuscular administration, patients with thrombocytopenia or a bleeding disorder may be administered the vaccine via subcutaneous injection.


    Children under 3 years
    Encephalopathy of unknown aetiology within 7 days previous pertussis vacc.
    Severe febrile conditions
    Uncontrolled epileptic disorder
    Uncontrolled neurological disorder

    Precautions and Warnings

    History of post vaccination pyrexia above 40 degrees C within 48 hours
    Previous post vaccination convulsions within 3 days
    Previous post vaccination crying for over 3 hours within 48 hours
    Previous post vaccination shock like state within 48 hours
    Immunodeficiency syndromes

    Postpone immunisation if there is active or suspected infection
    Impaired response possible in immunocompromised patients
    Vaccine may not be effective in 100% of patients
    May contain trace amounts of neomycin
    May contain trace amounts of polymyxin
    Do not mix with other vaccines in the same syringe
    Inject other vaccines at different sites
    Pertussis vaccination not routinely recommended in patients over 10 years
    Resuscitation facilities must be immediately available
    Establish full medical history and health status prior to vaccine
    Follow national immunisation guidelines

    Vaccination should be preceded by a review of the person's medical history (in particular previous vaccinations and possible adverse events). Administration of the vaccine should be carefully considered in patients who have a history of serious or severe reaction within 48 hours of a previous injection with a vaccine containing similar components.

    Administer with caution to patients with thrombocytopenia or a bleeding disorder since bleeding may occur following intramuscular administration. For both intramuscular and subcutaneous injections, firm pressure should be applied to the injection site for at least 2 minutes.

    Pregnancy and Lactation


    Diphtheria, tetanus, pertussis and poliomyelitis vaccine is not generally recommended during pregnancy, however the Department of Health has introduced a temporary programme since October 2012 to vaccinate pregnant women against pertussis with this vaccine. A single dose of the vaccine is to be administered between 28 to 38 weeks of pregnancy with 28 to 32 weeks being the optimal time for vaccination. Pregnant women should still be offered a single dose of the vaccine up to the onset of labour if they have missed the opportunity for vaccination at 28 to 38 weeks. While this programme is in place, women who become pregnant again should be offered vaccination during each pregnancy.

    Adequate data on the use of this vaccine during human pregnancy is not available. No teratogenic effect of vaccines containing diphtheria or tetanus toxoids, or inactivated poliovirus has been observed following use in pregnant women.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Diphtheria, tetanus, pertussis and poliomyelitis vaccine may be given during breastfeeding.

    Limited data on the use of this vaccine during breastfeeding is available. The vaccine contains toxoids and inactivated antigens, however no risk to the breastfed infant should be expected. The benefits versus the risk of administration to breastfeeding women should be evaluated by the health-care providers.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Abscess formation (injection site)
    Anaphylactic reaction
    Anaphylactoid reaction
    Attention disturbances
    Decreased appetite
    Dry throat
    Erythema at injection site
    Gastro-intestinal disturbances
    Guillain-Barre syndrome
    Haemorrhage (injection site)
    Hypotonic hyporesponsive episode
    Induration (injection site)
    Influenza-like syndrome
    Limb swelling
    Local pain (injection site)
    Oral herpes
    Sensation of warm and/or cold at injection site
    Sleep disturbances
    Swelling (injection site)
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last full review: June 2014

    Reference Sources

    Summary of Product Characteristics: Boostrix-IPV suspension for injection in pre-filled syringe. GlaxoSmithKline UK. Revised July 2020.

    Immunisation against infectious disease - the Green Book
    Available at:
    Last accessed: June 25, 2014

    NICE Evidence Services Available at: Last accessed: 27 June 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.